PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
- Conditions
- Cancer-related Fatigue
- Interventions
- Drug: Astragalus Polysaccharides 500 mgDrug: Astragalus Polysaccharides 250 mg
- Registration Number
- NCT01720550
- Lead Sponsor
- PhytoHealth Corporation
- Brief Summary
The objective of this study is to conduct a trial in the spirit of providing as much as possible the benefit of PG2 treatment to eligible patients and to evaluate the efficacy and safety of different doses of PG2 treatment for relieving fatigue among advanced cancer patients who are under standard palliative care (SPC) at hospice setting and have no further curative options available. Patient's fatigue status, to be measured by the Brief Fatigue Inventory-Taiwanese Form (BFI-T), will be the primary endpoint. The fatigue improvement response rate among patients between two study arms will then be compared as the basis for efficacy evaluation at the end of the first treatment cycle, and will be the primary endpoint. Other endpoints, the fatigue improvement response rate and the mean fatigue scores change from baseline among patients within and between cycles will be included in the secondary efficacy endpoints, and will be compared between two study arms. Patients' quality of sleep, appetite, pain, fatigue, nausea, vomiting and global quality of life (QoL) will be also measured by 11 questions (SS11) from EORTC(European Organization) for Research and Treatment of Cancer QLQ-C30 for secondary endpoint evaluation. The other secondary endpoints include Karnofsky performance scores, and weight change and its related c-reactive protein level of the patients.
- Detailed Description
This is a trial to evaluate use of different doses of PG2 treatment for fatigue improvement in advanced cancer patients who are under standard palliative care at hospice setting and have no further curative options available. Only patients who give consent to participate in this study and meet all other inclusion and exclusion criteria will be eligible to enroll into this study. All patients will continue the standard palliative care (SPC) during this study.
The main aim of this trial is to compare improvement of patient's fatigue status between patients with different doses of PG2 treatment. Patient's fatigue status will be assessed by the Brief Fatigue Inventory-Taiwanese (BFI-T) Form. Each patient's fatigue improvement response will be defined as an improvement in the mean fatigue scores by at least 10% from baseline. Other quality of life parameters will be measured by the 11 questions (SS11) of the EORTC QLQ-C30 and by Karnofsky performance scale. Patient's weight change and its related c-reactive protein will be followed. There are two study arms in this trial: 1) the PG2 High Dose arm; and 2) the PG2 Low Dose arm.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 323
- Signed the informed consent form
- ≧ 20 years old
- Have locally advanced or metastatic cancer or inoperable advanced cancer
- Under standard palliative care (SPC) at hospice setting and have no further curative options available
- BFI score ≧ 4
- Life expectancy of at least 3 months as determined by the investigator
- Willing and able to complete quality of life questionnaires
- Pregnant or breast-feeding
- Uncontrolled systemic disease
- Take central nervous system stimulators within 30 days before screening
- Have enrolled or have not yet completed other investigational drug trials within 30 days before screening
- Karnofsky Performance Scores less than 30 %
- Diagnosed as dying status
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PG2 High Dose Astragalus Polysaccharides 500 mg Astragalus Polysaccharides 500 mg PG2 Low Dose Astragalus Polysaccharides 250 mg Astragalus Polysaccharides 250 mg
- Primary Outcome Measures
Name Time Method Fatigue Improvement Response Rate 4 weeks Patient's fatigue status will be measured by the Brief Fatigue Inventory-Taiwanese Form (BFI-T). The fatigue improvement response rate among patients between two study arms will be compared as the basis for efficacy evaluation at the end of the first treatment cycle (4th week).
- Secondary Outcome Measures
Name Time Method Incidence of Adverse Events as a Measure of Safety and Tolerability 8 weeks Vital signs 8 weeks Karnofsky performance score 8 weeks The correlation between Weight change and the related blood c-reactive protein level 8 weeks The fatigue improvement response rate among patients within and between cycles (by BFI-T) 8 weeks The fatigue improvement by multiple BFI-T score percentage change levels among patients between two study arms 8 weeks The mean of patients' fatigue score change from baseline within and between cycles (by BFI-T) 8 weeks Symptoms and Quality of Life Assessments: SS11 from EORTC QLQ-C30 (including the evaluation of the quality of sleep, appetite, pain, fatigue, nausea, vomiting and global quality of life) 8 weeks Labolatory Safety Examination 8 weeks Included hematological, biochemical and urine examination
Immune Biomarkers 8 weeks This outcome specified for academic research was designed in add-on protocol (only submitted to IRB)
Physical Examination 8 weeks
Trial Locations
- Locations (9)
Chang Gung Memorial Hospital, Lovers Lake Branch
🇨🇳Keelung, Taiwan
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Chang Gung Memorial Hospital, Kaohsiung Branch
🇨🇳Kaohsiung City, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Chi Mei Hospital, Loiuying Campus
🇨🇳Tainan, Taiwan
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Taipei Medical University -Shung Ho Hospital
🇨🇳Taipei, Taiwan
Chang Gung Memorial Hospital, Linkou
🇨🇳Taoyuan, Taiwan